Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Artery embolization for migraines: hope or hype?

NCT ID NCT07652034

Knowledge-focused Sponsor: Cortex Neurovascular Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study follows 50 adults with migraines who have had or plan to have a procedure called middle meningeal artery embolization as part of their regular care. Researchers will look at how headache frequency, severity, medication use, and quality of life change over 12 months. The goal is to gather real-world data, not to test the procedure itself.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
middle meningeal artery embolization (procedure)
What this could lead to
If results are promising, this could point toward a larger trial to see if artery embolization is a safe and effective option for migraine relief.
What could go wrong
This is a small, early observational study, not a controlled trial. It cannot prove the procedure works, and results may not apply to all migraine patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Jul 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults aged 18 to 64 years with a diagnosis of migraine who have undergone or plan to undergo middle meningeal artery (MMA) embolization as part of routine clinical care at Cortex Neurovascular. Participants are enrolled in a prospective observational registry that accesses and analyzes clinical and patient-reported outcome data already documented during routine care. Enrollment does not influence clinical decision-making, procedural technique, device selection, or follow-up care.

Ages

18 to 64 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adults aged 18 to 64 years * Diagnosis of migraine * Have undergone or plan to undergo middle meningeal artery (MMA) embolization as part of routine clinical care, independent of study participation * Able and willing to provide informed consent * Able to read and understand English sufficiently to complete informed consent and patient-reported outcome assessments Exclusion Criteria: * Age under 18 years * Pregnancy at the time of enrollment * Inability to provide informed consent * Inability to read and understand English sufficiently to complete informed consent and patient-reported outcome assessments * Insufficient clinical or patient-reported outcome data for the planned analyses

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic migraine headache are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Headache headache disorder migraine disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Chronic migraine headache Migraine Migraine disorders

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Cortex Neurovascular / TRA Union

    Tacoma, Washington, 98405, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.